A portion of amino acids 424-453 from the human protein was used as the immunogen for this B-RAF antibody.
BRAF is a human gene, with the protein more formally known as serine/threonine-protein kinase B-Raf. The protein is involved in sending signals inside cells, which are involved in directing cell growth. Drugs that treat cancers driven by BRAF mutations have been developed. Two of these drugs, Vemurafenib and Dabrafenib are approved by FDA for treatment of late-stage melanoma. [Wiki]
The stated application concentrations are suggested starting amounts. Titration of the B-RAF antibody may be required due to differences in protocols and secondary/substrate sensitivity.
* VAT and and shipping costs not included. Errors and price changes excepted
